The chain's four leading drugstores made a net profit of 1 billion yuan in the first half of the year

On August 31st, the People's Big Pharmacy released its 2018 semi-annual report, and as of this moment, the four listed pharmacies of Dasinlin, One Heart, People's Big Pharmacy and Yifeng Pharmacy have handed over their half-yearly report card. Through the semi-annual report is not difficult to find that the four leading drugstore chains have maintained a high revenue growth rate, the highest growth rate of Yifeng 33.71 percent, the lowest 17.53 percent. In addition, industry consolidation is accelerating, the number of stores between the giants is growing, and this consolidation trend will continue.Revenue and profit "Qifei
compared with the common people, Dasinlin, One Heart Hall and Yifeng revenue can be seen, the first three are comparable in size, are more than 4 billion yuan, Yifeng pharmacy slightly inferior, only 2,993 million yuan. Among the four major drugstore chains, One Heart Hall became the most profitable drugstore chain in the first half of the year by a narrow margin of 292 million yuan.
It is worth mentioning that although Yifeng in the revenue gap with the other three larger, but the difference in net profit is not much, reached 225 million yuan, and in the common people, Dasinlin, One Heart Hall still maintained a growth rate of about 17%, Yifeng pharmacy growth rate reached 33.71 percent.
Yifeng earned a net profit of 225 million yuan with revenue of 2,993 million yuan, which has nothing to do with its high gross margin. Anxin Securities Research believes that, benefiting from the product structure continued to optimize the adjustment, fine-tuning operations, in the first half of 2018 Yifeng gross margin continued to improve, to 40.6%.Obsessive to open a shop, one heart is still riding dust
At present, the pharmaceutical retail industry concentration is low, the region's small and medium-sized drugstore chain more, in the industry policy changes have sought mergers and acquisitions opportunities, through the expansion of stores to compete for more market share. In recent years, the four major drugstore chains have accelerated the acquisition of new stores to compete for market share. Among them, the expansion rate of one-hearted stores is the most significant, currently has 5,264 stores, far more than the other three stores.
first heart to form a southwest as the core business area, South China as the strategic deep business area, North China as a supplementary business area pattern. Adhering to the "less regional high-density outlets" layout concept, in the provincial, municipal, county, township four types of market stores have more than 1000, forming a three-dimensional business pattern. As of August 24, 2018, One Heart Hall has 5,376 stores, including 3,390 in Yunnan, 519 in Guangxi, 186 in Guizhou, 618 in Sichuan, 269 in Shanxi, 167 in Chongqing, 10 in Shanghai, 8 in Tianjin, 200 in Hainan and 9 in Henan.
from the four listed drugstore chains themselves, we can also see that Yifeng's volume is currently the smallest, the number of stores is only 2499. But from the first half of the report, Yifeng is in a "catcher" role crazy "circle", trying to narrow the gap in the number of stores and geographical coverage.
Yifeng in this mid-year report during a total of 14 mergers and acquisitions, the expansion of the scope of Hunan, Hubei, Jiangsu, Guangdong, Jiangxi, Hebei, Shanghai and other places, reflecting its "regional focus, steady expansion" development strategy, in particular, nearly 1.4 billion acquisition of 86.31 percent of the new pharmacy as the largest hand.
addition, the common people and Dasanlin side is not willing to show weakness, the semi-annual report period, the common people added 534 stores, due to the company's development planning and business strategy adjustment closed 29 stores. During the reporting period, Dasinlin opened 449 stores in six provinces, including Guangdong, Guangxi, Henan, Jiangxi, Fujian and Zhejiang, and entered Hebei Province through equity participation and other investment chains.
, the big four semi-annual reports also sent a message that mergers and acquisitions will continue as the market changes. Xie Zilong, chairman and president of the People's Congress, also said at the Xipu meeting recently that the merger and reorganization of the industry had only just begun because of the fragmentation of Chinese drugstore chains. As you can see, "crazy circle" is still the top priority of the next work.embrace new technologies, Dasinlin is the most active
with the reform of the drug regulatory system, capital intervention, increased competition, pharmacies are gradually having a hard time. The new retailing of pharmaceuticals will accompany the transformation of pharmacies to health service providers, O2O delivery of medicines, and pharmaceutical e-commerce, bringing the possibility of "co-linking" pharmaceutical retailing. Recently, Ali Health announced a joint effort with Dongrentang Big Pharmacy, Nep king's Star Health Pharmacy, Jiuzhou Grand Pharmacy and Tiansheng Big Pharmacy and many other chain pharmacies, test water medicine new retail, is an example.
unique, the four major drugstore chains are also rubbing their hands, eager to try. This is especially the most active of the big ginseng forest. In the report, Dasinlin will "actively embrace new retail technologies such as artificial intelligence to improve store operating efficiency, build smart pharmacy pilots through cooperation with industry-focused retail technology platforms, and improve the operational efficiency of store retailing by improving the operational efficiency of store retailing, meeting the needs of customers for convenient shopping, and promoting key stores next." "Included in one of its six core competencies.
July 24 this year, DasinLin and WeChat Payment jointly built the first WeChat payment smart pharmacy landed in Guangdong, causing a huge response in the industry. In this smart pharmacy, users can use small programs to complete membership card registration, establish personal health files, but also in the pharmacy scene to taste fresh sweep code purchase, intelligent cash register, Chinese medicine online ordering, self-service vending machines and other rich in science and technology experience.
In the information construction, Internet technology empowerment, as early as 2014 to complete sap Hybris-based e-commerce platform construction, synchronous completion of HANA big data platform construction, independent construction of Hongxiang mobile application system. People's big pharmacy to build O2O health cloud platform, adhere to the B2C and O2O and re-route. Benefiting from information technology and Internet enabling, the membership management systems of the four listed chains have brought them sustained benefit growth.Seize the prescription outflow market, the various competing layout
On April 28, 2018, the General Office of the State Council issued the Opinions on Promoting the Development of "Internet plus Medical Health" (State Office issued No. 26 of 2018), which promotes the integration of the Internet and medical and health services, which clearly defines the pattern of e-prescription outflow, brings opportunities for patients to retail pharmacies, and further expands the drug retail market.
industry professional analysis, hospital prescription outflow, the situation of separation of medicine gradually formed, the pharmaceutical retail industry will usher in hundreds of billions of levels of incremental market. The general trend of prescription exoded is bound to benefit the pharmaceutical retail industry, and the first to benefit is the listed drugstore chain.
, pharmacy chains can take many forms of outsourcing, such as hospital side shops, DTP pharmacies, Internet plus pharmaceutical retailing, and prescription third-party platforms. In its semi-annual report, Dasinlin mentioned that it is actively participating in the development of medical reform policies, prescription outflow to undertake, new special drugs (DTP) varieties of channel development and introduction, to enhance the professionalism of new special pharmacies, access to door-slow special consultation and other qualifications. At the same time, but also with the major brands to carry out in-depth communication, and jointly undertake the work of prescription outflow.
At the same time, the semi-annual report also mentioned that in the next few years, retail pharmacies will continue to DTP professional pharmacies, distribution pharmacies, chronic disease management pharmacies, smart pharmacies and other innovative models of transformation. At the same time, through cooperation with the government, medical institutions, health care institutions and suppliers, accelerate the pace of new and acquired stores around the hospital.
On the common people's side, according to its 2017 annual report, it plans to make efforts in the next few years in six areas, such as endoennive development, extended development, commodity power, professional services, financial control and human resources, among which commodity power and professional services are mainly to prepare for the outsourcing of prescriptions.
the first half of 2018, Yifeng, under the overall strategic plan of "regional focus and steady expansion", also emphasized the innovation of the three business models of "to undertake hospital prescription outflow", "pharmaceutical e-commerce model" and "big health pharmacy".
Especially in the field of DTP pharmacies, the four major chains, led by Yifeng, The People, One Heart, and Dasinlin, are trying to use their chaining characteristics to enjoy the brand effect and geographical advantages of the end market in the DTP business area.
In the overall semi-annual report comparison, although the volume of the first, but with the increasing concentration of the industry, the other three are also struggling to catch up, and each has its own different advantages. At the same time, with the continued deepening of prescription exodus, the four major drugstore chains are interested in a piece of the pie, in the end who can share more, it is still unknown. (Sina Pharmaceuticals)